The COOH-terminus of the Alzheimer amyloid Aβ peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-associated amyloid deposits

References

• Siman R, Greenberg BD. Alzheimer's disease pathogenesis and therapy. Emerging Strategies in Neurotherapeutics: Basic and Clinical Perspectives, LM Pullan, J Patel. Humana Press, Totowa, NJ 1995, In press
   Google Scholar
• Savage MJ, Howland DS, Ali SM, Siedlak S, Perry G, Siman R, Scott RW, Greenberg BD. APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiology of Alzheimer's Disease, D. Dawbam, S. Allen. BIOS Scientific Publishers, Ltd., Oxford 1995, In press
   Google Scholar
• Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J Biol Chem 1994; 269: 17741–17748
   PubMed Web of Science ®Google Scholar
• Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X-D, McKay DM, Tintner R, Frangione B, Younkin SG. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992; 258: 126–129
   PubMed Web of Science ®Google Scholar
• Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of β-amyloid in the secretary pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 1993; 90: 2092–2096
   PubMed Web of Science ®Google Scholar
• Dovey HF, Suomensaari-Chrysler S, Lieberburg I, Sinha S, Keim PS. Cells with a familial Alzheimer's disease mutation produce authentic β-peptide. NeuroReport 1993; 4: 1039–1042
   PubMed Web of Science ®Google Scholar
• Suzuki N, Cheung TT, Cai X-D, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 1994; 264: 1336–1340
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992; 359: 325–327
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Ghetti B, Fadow M, Roses AD, Benson MD. Characterization of amyloid fibril β-peptide in familial Alzheimer's disease with APP717 mutations. Biochem Biophys Res Commun 1993; 197: 386–392
   PubMed Web of Science ®Google Scholar
• Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble β1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 1994; 145: 452–460
   PubMed Web of Science ®Google Scholar
• Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not cerebrospinal fluid. Biochem Biophys Res Commun 1994; 200: 1592–1603
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease. Neurobiol Aging 1989; 10: 387–395
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Kezdy FJ, Kisilevsky R. Amyloidogenesis as a therapeutic target in Alzheimer's disease. Ann Rep Med Chem 1991; 26: 229–238
   Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245–4249
   PubMed Web of Science ®Google Scholar
• Roher A, Wolfe D, Palutke M, KuKuruga D. Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 1986; 83: 2662–2666
   PubMed Web of Science ®Google Scholar
• Kang Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K, Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733–736
   PubMed Web of Science ®Google Scholar
• Prelli F, Castano E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 1988; 51: 648–651
   PubMed Web of Science ®Google Scholar
• Prelli F, Castano EM, van Duinen SG, Bots GThAM, Luyendijk W, Frangione B. Different processing of Alzheimer's β-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem Biophys Res Commun 1988; 151: 1150–1155
   PubMed Web of Science ®Google Scholar
• Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging. Brain Res 1988; 474: 100–111
   PubMed Web of Science ®Google Scholar
• Barrow CJ, Yasuda A, Kenny PTM, Zagorski G. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 1992; 225: 1075–1093
   PubMed Web of Science ®Google Scholar
• Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992; 267: 546–554
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693–4697
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Lansbury PT. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993; 73: 1055–1058
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Costa PR, Griffin RG, Lansbury PT. Models of the β protein C-terminus: Differences in amyloid structure may lead to segregation of “long” and “short” fibrils. J Am Chem Soc 1993; 116: 9741–9742
   Web of Science ®Google Scholar
• Miller DL, Papayannapoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993; 301: 41–52
   PubMed Web of Science ®Google Scholar
• Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Coffer RJ, Reardon IM, Zürcher-Neely HA, Heinrikson RL, Ball MJ, Greenberg BD. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993; 268: 3072–3083
   PubMed Web of Science ®Google Scholar
• Weinreb PH, Jarrett JT, Lansbury PT. Peptide models of a hydrophobic cluster at the C-terminus of the β-amyloid protein. J Am Chem Soc 1994; 116: 10835–10836
   Web of Science ®Google Scholar
• Fabian H, Szendrei GI, Mantsch HH, Greenberg BD, Ötvös L. Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form β-pleated sheets in vitro. Eur J Biochem 1994; 221: 959–964
   PubMedGoogle Scholar
• Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(PE), in senile plaques. Neuron 1995; 14: 456–466
   Web of Science ®Google Scholar
• Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K, Suzuki N, Shoji S, Mori H. Biochemical evidence for the long-tail form (Aβ1 -42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994; 205: 834–842
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Okada A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45–53
   PubMed Web of Science ®Google Scholar
• Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to β-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994; 667: 138–142
   PubMed Web of Science ®Google Scholar
• Murphy GM, Fomo LS, Higgins L, Scardina JM, Eng LF, Cordell B. Development of a monoclonal antibody specific for the COOH-terminal of β-amyloid 1-42 and its immunohistochemical reactivity in Alzheimers disease and related disorders. Am J Pathol 1994; 144: 1082–1088
   PubMed Web of Science ®Google Scholar
• Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM. Monoclonal antibody to the C-terminus of β-amyloid. NeuroReport 1994; 5: 2117–2120
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Sugihara S, Ishiguro K, Takashima A, Hirai S. Immunohistochemical analysis of COOH-termini of amyloid beta protein (AP) using end-specific antisera for Aβ40 and Aβ42 in Alzheimer's disease and normal aging. Amyloid: Int J Exp Clin Invest 1995; 2: 7–16
   Web of Science ®Google Scholar
• Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 1992; 267: 17082–17086
   PubMed Web of Science ®Google Scholar
• Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Cowing E, Ball MJ. β-Amyloid(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer's disease. Proc Nall Acad Sci USA 1993; 90: 10836–10840
   PubMed Web of Science ®Google Scholar
• Mullan M, Crawford F, Axelman K, Houlden H, Lilus L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of amyloid. Nature Genet 1992; 1: 345–347
   PubMed Web of Science ®Google Scholar
• Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 1992; 360: 672–674
   PubMed Web of Science ®Google Scholar
• Cai XD, Golde TE, Younkin SG. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 1993; 259: 514–516
   PubMed Web of Science ®Google Scholar
• Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ. Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994; 91: 11993–11997
   PubMed Web of Science ®Google Scholar
• Johnston JA, Cowbum RF, Norgren S, Wiehager B, Venizelos N, Winblad B, Vigo-Pelfrey C, Schenk D, Lannfelt L, O'Neill C. Increased β-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. FEBS Lett 1994; 354: 274–278
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Bogdanovic N, Appelgren H, Axelman K, Lilius L, Hansson G, Schenk D, Hardy J, Winblad B. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci Lett 1994; 168: 254–256
   PubMed Web of Science ®Google Scholar
• Hanger DP, Mann DMA, Neary D, Anderton BH. Molecular pathology of Alzheimer's disease in sporadic and familial Alzheimer's disease with mutations in the amyloid precursor protein. Biochem Soc Trans 1992; 20: 642–645
   PubMed Web of Science ®Google Scholar
• Tamaoka A, Odaka A, Ishibashi Y, Usami M, Sahara N, Suzuki N, Nukina N, Mizusawa H, Shoji S, Kanazawa I, Mori H. APP717 missense mutation affects the ratio of amyloid β protein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease brain. J Biol Chem 1994; 269: 32721–32724
   PubMed Web of Science ®Google Scholar
• Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, Van Duinen SG, Bots GTAM, Luyendijk W, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248: 1124–1126
   PubMed Web of Science ®Google Scholar
• Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Marting J-J, Hofman A, Van Broeckhoven C. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nature Genet 1992; 1: 218–221
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun 1991; 179: 1247–1254
   PubMed Web of Science ®Google Scholar
• Clements A, Walsh DM, Williams CH, Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid β/A4 peptide. Neurosci Lett 1993; 161: 17–20
   PubMed Web of Science ®Google Scholar
• Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, White JA, Bonnycastle L, Weber JL, Alonson ME, Potter H, Heston LL, Martin GM. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668–671
   PubMed Web of Science ®Google Scholar
• Suzuki N, Cheung TT, Cai X-D, Ötvös L, Gillespie SL, Ho L, Eckman CB, Golde TE, Younkin SG. Factors affecting production of secreted amyloid β protein ending at Aβ42,43. Soc Neurosci Abstr 1994; 20: 437
   Google Scholar
• Mann DMA. The pathological association between Down's syndrome and Alzheimer's disease. Mech Ageing Dev 1988; 43: 99–136
   PubMed Web of Science ®Google Scholar
• Goldgaber D, Lerman MI, McBride OW, Saffioti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimers disease. Science 1987; 235: 877–880
   PubMed Web of Science ®Google Scholar
• Neve RL, Finch EA, Dawes LR. Expression of the Alzheimer amyloid precursor protein gene transcripts in the human brain. Neuron 1988; 1: 669–677
   PubMed Web of Science ®Google Scholar
• Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimers disease: Allelic variation and receptor interactions. Neuron 1993; 11: 575–580
   PubMed Web of Science ®Google Scholar
• Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 9649–9653
   PubMed Web of Science ®Google Scholar
• Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991; 541: 163–166
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977–1981
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: Binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Commun 1993; 192: 359–365
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145: 1030–1035
   PubMed Web of Science ®Google Scholar
• Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994; 372: 92–94
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Giaccone G, Frangione B, Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett 1988; 93: 191–196
   PubMed Web of Science ®Google Scholar
• Giaccone G, Tagliavini F, Linoli G, Bouras C, Frigerior L, Frangione B, Bugiani O. Down's patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 1989; 97: 232–238
   PubMed Web of Science ®Google Scholar
• Ikeda S, Allsop D, Glenner GG. Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases: An immunohistochemical study using amyloid β-protein antibody. Lab Invest 1989; 60: 113–122
   PubMed Web of Science ®Google Scholar
• Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989; 135: 309–319
   PubMed Web of Science ®Google Scholar
• Standaert D, Lee VM-Y, Greenberg BD, Lowery DE, Trojanowski JQ. Molecular features of hypothalamic plaques in Alzheimer's disease. Am J Patholl 1991; 139: 681–691
   PubMed Web of Science ®Google Scholar
• Timmers WF, Tagliavini F, Haan J, Frangione B. Parenchymal preamyloid and amyloid deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis - Dutch type. Neurosci Lett 1990; 118: 223–226
   PubMed Web of Science ®Google Scholar
• Kawai M, Kalaria RN, Cras P, Siedlak SL, Velasco ME, Shelton ER, Chan HW, Greenberg BD, Perry G. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res 1993; 623: 142–146
   PubMed Web of Science ®Google Scholar
• Wisniewski HM, Frackowiak J, Zoltowska A, Kim KS. Vascular β-amyloid in Alzheimer's disease angiopathy is produced by proliferating and degenerating smooth muscle cells. Amyloid: Int J Exp Clin Invest 1994; 1: 8–16
   Web of Science ®Google Scholar
• Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Liebowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F amyloid precursor protein. Nature 1995; 373: 523–527
   PubMed Web of Science ®Google Scholar